Literature DB >> 24117345

Molecular analysis of ATP-sensitive K⁺ channel subunits expressed in mouse vas deferens myocytes.

Kazuomi Iwasa1, Hai-Lei Zhu, Atsushi Shibata, Yoshihiko Maehara, Noriyoshi Teramoto.   

Abstract

BACKGROUND AND
PURPOSE: ATP-sensitive K(+)(K(ATP)) channels, which are composed of K(IR)6.x associated with sulphonylurea receptor (SUR) subunits, have been detected in native smooth muscle cells, but it is currently not known which of these is expressed in mouse vas deferens myocytes. EXPERIMENTAL APPROACH: Pharmacological and electrophysiological properties of K(ATP) channels in mouse vas deferens myocytes were investigated using patch clamp techniques. Molecular biological analyses were performed to examine the properties of these K(ATP) channels. KEY
RESULTS: During conventional whole-cell recording, pinacidil elicited an inward current that was suppressed by glibenclamide, a sulfonylurea agent, and by U-37883A, a selective K(IR)6.1 blocker. When 0.3 mM ATP was added to the pipette solution, the peak amplitude of the pinacidil-induced current was much smaller than that recorded in its absence. When 3 mM UDP, GDP or ADP was included in the pipette solution, an inward current was elicited after establishment of the conventional whole-cell configuration, with potency order being UDP > GDP > ADP. These nucleoside diphosphate-induced inward currents were suppressed by glibenclamide. MCC-134, a SUR modulator, induced glibenclamide-sensitive K(ATP) currents that were similar to those induced by 100 μM pinacidil. In the cell-attached configuration, pinacidil activated channels with a conductance similar to that of K(IR)6.1. Reverse transcription PCR analysis revealed the expression of K(IR)6.1 and SUR2B transcripts and immunohistochemical studies indicated the presence of K(IR)6.1 and SUR2B proteins in the myocytes. CONCLUSIONS AND IMPLICATIONS: Our results indicate that native K(ATP) channels in mouse vas deferens myocytes are a heterocomplex of K(IR)6.1 channels and SUR2B subunits.
© 2013 The British Pharmacological Society.

Entities:  

Keywords:  KATP channels; KIR6.1; SUR2B; vas deferens myocytes

Mesh:

Substances:

Year:  2014        PMID: 24117345      PMCID: PMC3874703          DOI: 10.1111/bph.12437

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  28 in total

1.  Voltage-gated potassium currents in rat vas deferens smooth muscle cells.

Authors:  Maksym I Harhun; Aron Jurkiewicz; Neide H Jurkiewicz; Dmytro O Kryshtal; Michael F Shuba; Irina A Vladimirova
Journal:  Pflugers Arch       Date:  2003-04-04       Impact factor: 3.657

2.  Molecular analysis of the subtype-selective inhibition of cloned KATP channels by PNU-37883A.

Authors:  H Kovalev; J M Quayle; T Kamishima; D Lodwick
Journal:  Br J Pharmacol       Date:  2004-02-02       Impact factor: 8.739

3.  ATP-sensitive K(+) channels composed of Kir6.1 and SUR2B subunits in guinea pig gastric myocytes.

Authors:  Jae Hoon Sim; Dong K Yang; Young Chul Kim; Sung Jin Park; Tong Mook Kang; Insuk So; Ki Whan Kim
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2002-01       Impact factor: 4.052

4.  Competitive antagonism by glibenclamide of cromakalim inhibition of twitch contractions in rabbit vas deferens.

Authors:  M Eltze
Journal:  Eur J Pharmacol       Date:  1989-02-14       Impact factor: 4.432

5.  Inhibition by the putative potassium channel opener pinacidil of the electrically-evoked release of endogenous dopamine and noradrenaline in the rat vas deferens.

Authors:  P Soares-da-Silva; M H Fernandes
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-10       Impact factor: 3.000

6.  Cyclic AMP-mediated inhibition of noradrenaline-induced contraction and Ca2+ influx in guinea-pig vas deferens.

Authors:  K Kato; K Furuya; I Tsutsui; T Ozaki; S Yamagishi
Journal:  Exp Physiol       Date:  2000-07       Impact factor: 2.969

7.  MCC-134, a novel vascular relaxing agent, is an inverse agonist for the pancreatic-type ATP-sensitive K(+) channel.

Authors:  T Shindo; Y Katayama; Y Horio; Y Kurachi
Journal:  J Pharmacol Exp Ther       Date:  2000-01       Impact factor: 4.030

8.  Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor.

Authors:  N Inagaki; T Gonoi; J P Clement; N Namba; J Inazawa; G Gonzalez; L Aguilar-Bryan; S Seino; J Bryan
Journal:  Science       Date:  1995-11-17       Impact factor: 47.728

9.  K channel activation by nucleotide diphosphates and its inhibition by glibenclamide in vascular smooth muscle cells.

Authors:  D J Beech; H Zhang; K Nakao; T B Bolton
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

10.  The Concise Guide to PHARMACOLOGY 2013/14: overview.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; John C McGrath; William A Catterall; Michael Spedding; John A Peters; Anthony J Harmar; N Abul-Hasn; C M Anderson; C M H Anderson; M S Araiksinen; M Arita; E Arthofer; E L Barker; C Barratt; N M Barnes; R Bathgate; P M Beart; D Belelli; A J Bennett; N J M Birdsall; D Boison; T I Bonner; L Brailsford; S Bröer; P Brown; G Calo; W G Carter; W A Catterall; S L F Chan; M V Chao; N Chiang; A Christopoulos; J J Chun; J Cidlowski; D E Clapham; S Cockcroft; M A Connor; H M Cox; A Cuthbert; F M Dautzenberg; A P Davenport; P A Dawson; G Dent; J P Dijksterhuis; C T Dollery; A C Dolphin; M Donowitz; M L Dubocovich; L Eiden; K Eidne; B A Evans; D Fabbro; C Fahlke; R Farndale; G A Fitzgerald; T M Fong; C J Fowler; J R Fry; C D Funk; A H Futerman; V Ganapathy; B Gaisnier; M A Gershengorn; A Goldin; I D Goldman; A L Gundlach; B Hagenbuch; T G Hales; J R Hammond; M Hamon; J C Hancox; R L Hauger; D L Hay; A J Hobbs; M D Hollenberg; N D Holliday; D Hoyer; N A Hynes; K-I Inui; S Ishii; K A Jacobson; G E Jarvis; M F Jarvis; R Jensen; C E Jones; R L Jones; K Kaibuchi; Y Kanai; C Kennedy; I D Kerr; A A Khan; M J Klienz; J P Kukkonen; J Y Lapoint; R Leurs; E Lingueglia; J Lippiat; S J Lolait; S C R Lummis; J W Lynch; D MacEwan; J J Maguire; I L Marshall; J M May; C A McArdle; J C McGrath; M C Michel; N S Millar; L J Miller; V Mitolo; P N Monk; P K Moore; A J Moorhouse; B Mouillac; P M Murphy; R R Neubig; J Neumaier; B Niesler; A Obaidat; S Offermanns; E Ohlstein; M A Panaro; S Parsons; R G Pwrtwee; J Petersen; J-P Pin; D R Poyner; S Prigent; E R Prossnitz; N J Pyne; S Pyne; J G Quigley; R Ramachandran; E L Richelson; R E Roberts; R Roskoski; R A Ross; M Roth; G Rudnick; R M Ryan; S I Said; L Schild; G J Sanger; K Scholich; A Schousboe; G Schulte; S Schulz; C N Serhan; P M Sexton; D R Sibley; J M Siegel; G Singh; R Sitsapesan; T G Smart; D M Smith; T Soga; A Stahl; G Stewart; L A Stoddart; R J Summers; B Thorens; D T Thwaites; L Toll; J R Traynor; T B Usdin; R J Vandenberg; C Villalon; M Vore; S A Waldman; D T Ward; G B Willars; S J Wonnacott; E Wright; R D Ye; A Yonezawa; M Zimmermann
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.